Join
Live feed
·
INSIDERFilingvia Quantisnow
Relay Therapeutics Inc. logo

Chief Financial Officer Catinazzo Thomas sold $14,376 worth of shares (972 units at $14.79), decreasing direct ownership by 0.45% to 212,895 units (SEC Form 4) to satisfy tax liability

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.